A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment

Inclusion Criteria: * Male or female, aged between 6 months and 17 years at the baseline visit. * Patients with AD who have been prescribed dupilumab as per clinical practice (according to AIFA reimbursement policy) and who fulfill the following criteria: \-- Adolescents (12 to 17 years old) with EASI \< 16 and children (6 months to 11 years of age) with EASI \< 21 and. 1. Children's Dermatology Life Quality Index (cDLQI)\* ≥ 10 and / or 2. Itch NRS ≥ 7 and / or 3. Localization in visible or sensitive areas (head/neck/hands or genitals) * Participants/ caregivers able to understand and complete study-related questionnaires. * Provided signed informed consent or parental/legally acceptable representative consent and participant assent where applicable. * Only for adolescents and children 6-11 years of age. Exclusion Criteria: * Use of dupilumab within 6 months prior to study entry. * Participants currently participating in any interventional clinical trial that modifies patient care. * Any condition that, in the opinion of the Investigator, may interfere with participant's ability to participate in the study (e.g., substance abuse). The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.